InflaRx FY2024 EPS Estimate Decreased by Leerink Partnrs

InflaRx (NASDAQ:IFRX) – Research analysts at Leerink Partnrs decreased their FY2024 earnings per share estimates for InflaRx in a research report issued on Monday, November 11th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($1.02) per share for the year, down from their previous estimate of ($0.99). The consensus estimate for InflaRx’s current full-year earnings is ($1.01) per share. Leerink Partnrs also issued estimates for InflaRx’s Q4 2024 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.01) EPS and FY2026 earnings at ($0.93) EPS.

Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of InflaRx in a research report on Monday.

InflaRx Price Performance

NASDAQ IFRX opened at $1.71 on Thursday. InflaRx has a 1-year low of $1.17 and a 1-year high of $2.10. The business has a 50 day simple moving average of $1.53 and a two-hundred day simple moving average of $1.51. The stock has a market capitalization of $100.68 million, a PE ratio of -1.58 and a beta of 1.57.

Hedge Funds Weigh In On InflaRx

An institutional investor recently raised its position in InflaRx stock. Ikarian Capital LLC raised its position in shares of InflaRx (NASDAQ:IFRX) by 2.4% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 704,987 shares of the company’s stock after acquiring an additional 16,383 shares during the period. Ikarian Capital LLC owned approximately 1.20% of InflaRx worth $1,086,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.